Back to Search
Start Over
Emerging immunotherapy for the treatment of esophageal cancer
- Source :
- Expert opinion on investigational drugs. 25(6)
- Publication Year :
- 2016
-
Abstract
- Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer.Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications.Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Esophageal Neoplasms
Immune checkpoint inhibitors
medicine.medical_treatment
Cancer Vaccines
Immunotherapy, Adoptive
Cell therapy
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Pharmacology (medical)
Pharmacology
business.industry
Cancer
General Medicine
Immunotherapy
Esophageal cancer
medicine.disease
Prognosis
Cancer treatment
Survival Rate
030104 developmental biology
Treatment modality
030220 oncology & carcinogenesis
Immunology
Cancer vaccine
business
Subjects
Details
- ISSN :
- 17447658
- Volume :
- 25
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Expert opinion on investigational drugs
- Accession number :
- edsair.doi.dedup.....15e0a515ff3b38265a1f733a26459213